由于L-Dopa诱导的动力障碍,需要多巴胺2受体的 cholinergic 内部神经元表达
bioRxiv : the preprint server for biology
|May 20, 2024
概括
向D2受体在条状胆固醇内神经元 (CIN) 上可以减少L-Dopa诱导的动力障碍 (LID). 在CIN减弱的LID和关键分子标记物中消灭D2受体,突出显示帕金森病治疗中的D2-CIN信号.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 状胆固醇内部神经元 (CIN) 驱动L-Dopa诱导的运动障碍 (LID).
- 导致LID中异常CIN活性的信号通路尚未完全理解.
- CIN上的D2和D5受体与L-多巴反应有关,而D2的作用尚未得到充分探索.
研究的目的:
- 调查D2受体在LID发展中的作用,特别是CIN上的D2受体.
- 要确定在CIN上是否需要D2受体激活,以使L-Dopa诱导功能障碍.
主要方法:
- 使用具有特定于CIN的D2受体剥离 (D2CINKO) 的小鼠.
- 动物接受了单边的6-OHDA损伤和慢性L-Dopa治疗.
- 量化了LID严重程度,组织学标记 (p-ERK) 和CIN活性 (p-rpS6).
主要成果:
- D2 CIN KO在各种L-Dopa剂量中显著减轻了LID严重程度.
- 在D2 CIN KO小鼠中观察到LID标记物p-ERK的减少表达.
- 在背侧条纹体中,L-Dopa诱导的CIN活性标志物p-rpS6的增加被阻止.
结论:
- 特别是在CIN上的D2受体激活是LID的关键驱动因素.
- 针对CIN上的D2受体代表了管理帕金森病中L-Dopa诱导的副作用的潜在治疗策略.
相关概念视频
01:24Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309
01:15Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.1K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.1K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
661
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
661